X-ZELL technology used in development of new T cell therapy Singapore, September 2023 – A research team at Duke-NUS Medical School in Singapore has developed a T cell therapy that could play an important role in treating cancer recurrences after liver transplants. The...
First lab confirmed to introduce X-ZELL Cryoimmunostaining™ into clinical routine Frankfurt, June 2023 – X-ZELL, a pioneering company in the field of next-generation cytology, is proud to announce a strategic collaboration with the Medizinisches Versorgungszentrum für...
Former Roche Diagnostics NAM CEO Michael Tillmann joins X-ZELL executive board Singapore, August 2022 – X-ZELL is proud to announce the appointment of Michael Tillmann as member of the company’s executive board. Drawing on more than 30 years of experience in the...
X-ZELL appoints Sebastian Grote as Managing Director Singapore, March 2022 – Singaporean medical technology specialist X-ZELL has appointed Sebastian Grote as Managing Director, effective from 1 March 2022. Grote previously served as Head of Marketing & Strategy...
Circulating atypical cells detected in blood of lung cancer patients Warsaw, October 2021 – New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating...
X-ZELL hMX™ technology now available for research use Singapore, September 2021 – X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide. Previously exclusive to X-ZELL, the patented system is part of the...
